Clinical Trial Update: Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the triplet combination venetoclax, lenalidomide, and rituximab in patients with previously untreated mantle cell lymphoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING